In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Amneal and Impax Labs merge to create leading generics company

Executive Summary

Amneal Pharmaceuticals LLC and Impax Laboratories Inc. entered into a merger agreement in which the two companies will combine in an all stock transaction valued at approximately $6.2bn in market value (assumes per share price of $19.95) or $8.7bn in enterprise value (including net debt of $2.5bn; 4.8x and 13.9x EV to 2017 combined pro forma revenue and EBITDA, respectively).
Deal Industry
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
      • Macromolecule
      • Topical Delivery
      • Transdermal
    • Generic Drugs
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Payment Includes Stock

Related Companies

Advertisement
UsernamePublicRestriction

Register